Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a safer start to a key CLL drug be possible? new study reexamines the risk

NCT ID NCT07691047

Disease control Sponsor: Private Hospital of Confluent, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at people with chronic lymphocytic leukemia (CLL) who are about to start treatment with venetoclax, a targeted therapy. Doctors want to see if starting with other drugs first lowers the risk of tumor lysis syndrome, a dangerous side effect where cancer cells break down too quickly. By reassessing this risk, the goal is to simplify prevention steps and make treatment safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
venetoclax
What this could lead to
If successful, this could simplify how doctors manage the risk of tumor lysis syndrome, potentially reducing hospital stays and making treatment safer for CLL patients.
What could go wrong
This is an observational reassessment, not a test of a new drug. The findings may not change current practice if the risk remains high or if the simplified approach proves unsafe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with chronic lymphocytic leukemia/lymphocytic lymphoma * Meeting the treatment criteria according to iwCLL 2018 * Eligible for treatment with venetoclax in combination with a Bruton's tyrosine kinase inhibitor (ibrutinib, other approved generations) or obinutuzumab * First-line treatment or relapse Exclusion Criteria: * Patients with meningeal and/or cerebral involvement * Patients with an active, uncontrolled infection * Patients scheduled to receive venetoclax monotherapy or rituximab-venetoclax according to the MURANO study regimen (Murano regimen: venetoclax is administered before rituximab) * Contraindications to contrast-enhanced CT scanning (severe renal insufficiency, documented allergy to contrast agents). * Pregnancy or breastfeeding * Individuals deprived of their liberty, under legal guardianship, or under conservatorship * Dementia, mental impairment, or psychiatric disorder that could compromise the patient's ability to provide informed consent and/or to adhere to the protocol and follow-up requirements of the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphoid leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Leukemia, B-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphoid leukemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinique de l'Europe

    Amiens, France

  • Hôpital Privé du Confluent

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.